Microbot Medical's LIBERTY System Powers 'World's First' Robotic Endovascular Procedures at Emory Healthcare
MBOT sits 86% above its 52-week low of $1.35 on light trading volume (0.4× avg).
Summary
Emory Healthcare has successfully utilized Microbot Medical's LIBERTY Endovascular Robotic System to perform "world's first" robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia and robotic Y-90 radioembolization mapping for liver cancer. This significant milestone demonstrates the system's versatility and precision across complex vascular conditions. For a small-cap medical device company, successful adoption and pioneering procedures at a reputable institution like Emory Healthcare provide strong validation for the LIBERTY system's capabilities and commercial potential. This event is a crucial step in the company's market penetration strategy, following its Limited Market Release in November 2025. Investors will be watching the upcoming Full Market Release at the Society of Interventional Radiology conference in April 2026 for further signs of market adoption and revenue growth.
At the time of this announcement, MBOT was trading at $2.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.9M. The 52-week trading range was $1.35 to $4.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.